12:08 PM EST - Knight Therapeutics Inc. : Announced today that privately-held Triumvira Immunologics Inc. has repaid the outstanding loan balance of US$5 million issued in 2019. In addition, Knight continues to hold rights to commercialize Triumvira’s future approved products in select countries if certain conditions are met. Knight Therapeutics Inc.
shares T.GUD are trading up $0.20 at $7.12.
